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Mitochondrial biogenesisObesity is a complex disease caused by the interaction of a myriad of genetic, dietary, lifestyle and
environmental factors, which favors a chronic positive energy balance, leading to increased body fat mass.
There is emerging evidence of a strong association between obesity and an increased risk of cancer. However,
themechanisms linking both diseases are not fully understood. Here, we analyze the current knowledge about
the potential contribution that expanding adipose tissue in obesity could make to the development of cancer
via dysregulated secretion of pro-inﬂammatory cytokines, chemokines and adipokines such as TNF-α, IL-6,
leptin, adiponectin, visfatin and PAI-1. Dietary factors play an important role in the risk of suffering obesity and
cancer. The identiﬁcation of bioactive dietary factors or substances that affect some of the components of
energy balance to prevent/reduce weight gain as well as cancer is a promising avenue of research. This article
reviews the beneﬁcial effects of some bioactive food molecules (n-3 PUFA, CLA, resveratrol and lipoic acid) in
energy metabolism and cancer, focusing on the molecular mechanisms involved, which may provide new
therapeutic targets in obesity and cancer. This article is part of a Special Issue entitled: Bioenergetics of Cancer.ergetics of Cancer.
liaga).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Energy balance and obesity
The concept of energy balance involves the exact equilibrium
between caloric intake and energy utilization. Energy expenditure
takes the form of physical activity, basal metabolism, and adaptive
thermogenesis [1]. Physical activity refers to all voluntary movement,
while basal metabolism includes the myriad biochemical processes
necessary to sustain life. Adaptive thermogenesis refers to energy
dissipated in the form of heat in response to environmental changes,
such as diet or exposure to cold. In this context, it should be pointed
out that the boundary between what is considered basal metabolism
versus adaptive thermogenesis is not always clear-cut [1]. Obesity is
deﬁned as an abnormal or excessive fat accumulation that involves a
risk to health. The fundamental cause of overweight or obesity is a
positive energy balance, in which energy intake exceeds energy
expenditure over a prolonged time leading to the increased bodymass
including the accumulation of subcutaneous and visceral fat [2].
However, obesity is a complex disease caused by different factors such
as genetic, diet, lifestyle and environmental factors [3]. Some studies
estimated that 40–70% of the variation in obesity-related phenotypes
could be heritable [4]. In most of cases, obesity appears as a polygeniccondition that is additionally affected by a myriad of environmental
factors. In fact, the development of overweight and obesity is a
consequence of the easy and cheap availability of high-calorie yielding
foods, which is combined with sedentary lifestyle changes, occurring
in modern societies and affecting genetically predisposed subjects
(Fig. 1).
The prevalence of obesity among children, adolescents and adults
has been dramatically increasing during the last decades [5,6]. The
World Health Organization (WHO) estimates that there are currently
more than 1.6 billion overweight adults and at least 400 million of
these are obese. Moreover, they predict that by 2015 approximately
2.3 billion adults will be overweight and more than 700 million will
be obese [7]. Thus, obesity is acquiring the characteristics of an
authentic pandemia and it has been recognized as one of the major
global health problems. Indeed, this health hazard is linked to several
types of common diseases including cardiovascular disease [8], type 2
diabetes mellitus [9,10], hypertension, dyslipidemia, liver disease and
also various types of cancer [9,11,12]. Therefore, the health con-
sequences of obesity are huge and varied, ranging from an increased
risk of premature death to several non-fatal but debilitating diseases
that have adverse effects on the quality of life.
Furthermore, obesity typically leads to insulin and leptin resis-
tance and a shift to dysfunctional adipose tissue. These conditions
cause metabolic dysregulation with elevated circulating fatty acids
and an increased secretion of pro-inﬂammatory adipokines. When left
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hypertension, atherosclerosis and cardiovascular disease [13,14]. The
association between hypertension and obesity is well documented.
Both systolic and diastolic blood pressure increase with BMI (Body
Mass Index). Thus, obese people present higher risk to develop
hypertension in comparison with lean people [15]. Obese individuals
are frequently characterized by an impaired lipid proﬁle, in which
plasma triglycerides are raised, HDL-cholesterol concentrations are
reduced and low-density lipoprotein apo B (LDL-apoB) levels are
raised. This disturbed metabolic proﬁle is more often seen in obese
patients with a high accumulation of intra-abdominal fat and has
consistently been related to an increased risk of cardiovascular
diseases [16,17]. A positive association between obesity and the risk
of developing type 2 diabetes mellitus has been also repeatedly
reported in different studies. Intra-abdominal fat accumulation, has
been associated with an increased risk of prediabetic conditions such
as impaired glucose tolerance and insulin resistance [18].
Nonalcoholic fatty liver disease (NAFLD) is another of the conse-
quences of the current obesity epidemic and the hepatic manifestation
of the metabolic syndrome. This term encompasses a clinicopath-
ologic spectrum of disease ranging from isolated hepatic steatosis to
nonalcoholic steatohepatitis (NASH), the more aggressive form of
fatty liver disease and characterized by steatosis, inﬂammation and
progressive ﬁbrosis, ultimately leading to cirrhosis and end-stage liver
disease [19]. The most widely accepted theory that explains the
pathogenesis of NASH is titled the ‘Two Hit Theory’ resulting from fatty
inﬁltration of the liver due to obesity and insulin resistance, followed
by inﬂammatory insults, potentially due to oxidative stress [20]. Recent
studies estimate that NAFLD affects 30% of the general population and
as high as 90% of the morbidly obese [21]. Furthermore, obese patients
are at particularly high risk for NASH in view of the frequent co-
existence of other features of the metabolic syndrome; thus, the
prevalence of NASH in those patients ranges from 20%–30% against
5%–7% in the general population [22]. Although patients with isolated
steatosis generally have a benign prognosis, some 26–37% of patients
with NASH demonstrate progression of ﬁbrosis over time period of up
to 5.6 years, with up to 9% progressing to cirrhosis [23]. BMI and
diabetes constitute independent risk factors associated with the
progression of ﬁbrosis [24]. Thus, it has been reported that aboutFig. 1. Fundamental principles of energy balance. A positive energy balance occurs when
Conversely, a negative energy balance promotes weight loss.40%–62% of patients with NASH-related cirrhosis develop a complica-
tion of cirrhosis after 5–7 years of follow-up [25]. The increase in the
prevalence of childhood obesity results in a rising prevalence of
metabolic syndrome and type 2 diabetes in populations. NASH was
ﬁrst observed in children in 1983 as a pattern of liver injury and it can
even develop in obese children under 10 years of age [26]. The
signiﬁcant relation between fasting insulin, insulin resistance and
NAFLD in obese children underlines the clinical dimension of these
metabolic disturbances [27].
On the other hand, obesity is considered a major risk factor for
the development and progression of sleep apnea [28]. Sleep apnea
can be a problem with serious implications for anesthetic manage-
ment, surgery, effect on pulmonary hypertension, stroke coronary
artery disease and cardiac arrhythmias [29]. In addition, sleep apnea
has a strong correlation with glucose metabolism [30]. Recently, the
association between obesity and kidney disease onset has been ac-
cepted since several epidemiological and pathological studies support
this relationship. A number of epidemiological studies have also
provided sufﬁcient evidence of a positive association between obe-
sity and the incidence of cancer, particularly of hormone-dependent
and gastrointestinal cancers. Modulation of energy balance, through
increased physical activity, reduced the risk of many cancers, in-
cluding cancers of the colon, breast and endometrium. In this context,
it has been shown that weight loss by dietary and physical activity
interventions partially reverse metabolic, endocrinal, inﬂammatory,
and renal alterations associated with obesity [31].
2. Obesity and cancer
Energy imbalance is associated with obesity and different studies
have observed a relationship between obesity and cancer [32–35].
The concept of a relationship between dysregulated metabolism
and carcinogenesis was ﬁrst enunciated by Otto Warburg [36]. In
2002, the International Agency for Research on Cancer (IARC) expert
panel evaluated the link between weight and cancer [37] and
concluded that some cancers could be prevented by avoiding weight
gain. Since the IARC report, many observational and epidemiological
studies have further investigated the association between adiposity
and cancer, suggesting that obesity is associated with a signiﬁcantlyenergy intake is greater that energy expenditure and promotes weight gain/obesity.
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colon [38], esophagus, breast (in postmenopausal women) [39],
endometrium, kidney, liver, gallbladder and pancreas [5,11,35,39,40].
Obesity management is an opportunity for cancer prevention [41],
and adipose tissue has been suggested as a target organ in the
treatment of hormone-dependent breast cancer and other types of
cancer.
2.1. Obesity and breast cancer
Breast cancer is the second most common cancer in the world and
the most common neoplasia among women. The association between
indicators of body size and risk of breast cancer has been examined in
numerous studies [42–44]. Obesity increases breast cancer risk in
postmenopausal women by around 50%, probably by increasing
serum concentrations of free estradiol [42,43,45]. Interestingly several
studies established that the association between body size and the
risk of breast cancer differed according to menopausal status [46,47].
In fact, BMI and body weight have been found to be positively related
to the risk of breast cancer among postmenopausal women whereas
some studies found inverse associations [11]. Furthermore, abdominal
adiposity has been found to be positively associated with a higher risk
of breast cancer in postmenopausal women, this relationship being
stronger among nonhormone-replacement therapy users than among
hormone replacement therapy users [48,49].
However, the mechanisms that underlie the association between
obesity and breast cancer risk are not completely understood. Several
hypotheses have been proposed, including alterations in sex hor-
mones, growth factors and cytokines [11]. Another mechanism by
which obesity may induce the development of breast cancer involves
insulin and/or Insulin-like growth factors (IGFs) [50].
2.2. Obesity and endometrial cancer
There is convincing and consistent evidence from both case–
control and cohort studies that overweight and obesity are strongly
associated with endometrial cancer [51,52]. In fact, the risk of
developing endometrial cancer is about 2 to 3-fold higher in obese
women than in leanwomen [53] and about 40% of endometrial cancer
incidence has been estimated to be attributable to excess body weight
[54]. As with breast cancer, the potential mechanism for the increase
risk of endometrial cancer associated with obesity is the increase in
circulating estrogens [6].
2.3. Obesity and colorectal cancer
Colorectal cancer is the third most common cancer in the world.
Incidence rates are approximately 10-fold higher in developed than in
developing countries [53]. A possible association between an excess of
body weight and risk of colon cancer has been examined in many
epidemiological and cohort studies which have concluded that
obesity is related with a higher risk of colorectal cancer [33,54,55].
Different studies have suggested that waist circumference and the
waist/hip ratio are also strongly related to a higher risk of colorectal
cancer and large adenomas in men, as supported by European
Prospective Investigation into Cancer and Nutrition (EPIC), whereas
body weight and BMI are associated with colon cancer risk in men but
not in women [56,57]. The reasons for the gender difference are
speculative. One hypothesis is that abdominal adiposity, more
common in men than in women, is a stronger predictor of colon
cancer risk than peripheral adiposity [58]. However, the mechanisms
involved in the association between abdominal obesity and increased
colon cancer risk remains still unclear. Another possible explanation is
the protective role of exogenous estrogens on the risk of colorectal
cancer [59].2.4. Obesity and prostate cancer
Prostate cancer is the cancer most frequently diagnosed in men in
Europe [60]. More than 40 studies, including prospective and case–
control studies, examining the association between obesity and risk of
prostate cancer have provided conﬂicting results [61]. However, a
recent meta-analysis has suggested a weak signiﬁcant positive
association with an estimated increase in prostate cancer risk (5%
excess risk per 5 unit increment of BMI) [62]. The association between
waist circumference or waist hip-ratio and risk of prostate cancer has
been examined in only a very few studies with most studies reporting
no signiﬁcant associations [62,63].
2.5. Obesity and esophageal cancer
Obesity is associated with a 3-fold increase in risk for adenocar-
cinoma of the esophagus [6,64]. The link between obesity and risk of
esophageal cancer has recently been conﬁrmed by quantitative meta-
analysis that included twelve case–control studies and two cohort
studies [65]. High BMI is associated with gastroesophageal reﬂux and
frequent reﬂux is very strongly associated with esophageal adeno-
carcinoma [66,67]. Thus the increased occurrence in gastroesophageal
reﬂux itself is considered to be a major risk factor for esophageal
cancer.
2.6. Obesity and liver cancer
Primary liver cancer is one of themost common and deadly cancers
worldwide. Incidence is increasing and hepatocellular carcinoma
(HCC) has risen to become the ﬁfth most common cancer and the
third leading cause of cancer death [68,69]. Obesity has been estab-
lished as a signiﬁcant risk factor for liver diseases. A large prospective
mortality study, demonstrated that high BMI was signiﬁcantly
associated with higher rates of liver cancer-related death. Compared
to patients with normal BMI, the relative risk of mortality from liver
cancer was 1.68 times higher in women and 4.52 times higher in men
with BMIN35 kg/m2 [51]. Similarly, data obtained from the United
Networkof OrganSharing (UNOS) database on all liver transplantation
from 1991 to 2000 carried out in the United States showed that
the overall incidence of HCC in patients undergoing liver transplan-
tation was 3.4% with a slightly higher prevalence among obese
patients at 4.0%. Moreover, in this study obesity was conﬁrmed to be
an independent risk factor for HCC in patients with alcoholic cirrhosis
(odds ratio [OR], 3.2) and cryptogenic cirrhosis (OR, 11.1) [70]. Obesity
has deﬁnitively been established as a risk factor for the development
of HCC. It is likely that this association represents the progression
of underlying NAFLD to cirrhosis, but it remains unclear whether
cirrhosis is a necessary prerequisite for the development of HCC [71].
Animal models of NAFLD support the hypothesis that obesity-related
metabolic abnormalities, rather than cirrhosis, initiate the hepatic
neoplastic process during obesity [72].
2.7. Other types of cancer
Obesity has also been linked to other types of cancer, although
overall the amount of studies or data available is still limited. Several
recent studies have suggested that high BMI may be associated with
approximately a doubling of risk for pancreatic cancer in men and
women [6]. Moreover, a recent meta-analysis supports a positive
relationship between BMI and risk of pancreatic cancer [73]. However,
in the study from the EPIC cohort, the BMI was not found to be
signiﬁcantly associated with pancreatic cancer. Two further studies
have found some evidence for a positive association with waist
circumference in men but not in women [74,75].
The role of obesity on ovarian cancer survival is unclear but it has
been suggested that obesity may affect ovarian cancer survival by
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and increasing the likelihood of postoperative complications [76].
Few studies have investigated the association of BMI with cancers
of gallbladder, stomach and uterine cervix but data are limited and
inconsistent [32,77].
In summary, these studies have demonstrated that there is a clear
association between obesity and different types of cancer (specially,
breast, esophageal, colorectal…). However, the biological mecha-
nisms that link overweight and obesity to different forms of cancer,
other than those with an endocrine component, are poorly under-
stood. Thus, further research to deﬁne the causal role of obesity in
these types of cancers is needed.
3. Role of dysfunctional adipose tissue
Obesity is strongly associated with changes in the physiological
function of adipose tissue, leading to insulin resistance, chronic
inﬂammation, and altered secretion of adipokines [78]. White adipose
tissue (WAT) is a complex and metabolically active organ, with a
relevant important role in regulating whole-body metabolism.WAT is
the largest energy storage organ, having an important lipid storing
capacity in periods when energy input exceeds energy expenditure
and with a lipolytic function (release of NEFA) during energy
deprivation [1,79]. In addition to its primary role as a fuel reservoir,
white adipose tissue has been conﬁrmed as a major endocrine organ,
since the tissue synthesizes and secretes an array of sex steroids, and
bioactive peptides termed ‘adipokines’, involved in the physiological
regulation of fat storage, energy metabolism, food intake, insulin
sensitivity, and immune function among others [80]. In fact, adipose
tissue dysfunction might play a crucial role in the different obesity-
linked diseases including inﬂammation, insulin resistance and cancer.
Several of these factors, such as insulin resistance, chronic inﬂamma-
tion, decreased levels of adiponectin, increased levels of plasminogen
activator inhibitor-1 (PAI-1), endogenous sex steroids, visfatin and
leptin, could be involved in carcinogenesis and cancer progression. In
this section, we will review the pathophysiological mechanisms
linking obesity to cancer, focusing on adipose tissue dysfunction as a
potential unifying causal factor [78].
3.1. Sex steroids
WAT is an active organ that secretes different sex steroids. Obesity
has an important impact on the synthesis and bioavailability of
endogenous sex steroids. Indeed, obesity is associated with an
increased serum concentration of estradiol and estrone and a
decreased serum concentration of testosterone. Increased levels of
estradiol are the result of the peripheral conversion of androgens to
estradiol by an overall increased aromatase activity in WAT,
secondary to the enhanced total adipose tissue mass [81]. In addition,
obesity is associated with increased insulin and bioactive IGF-1 levels
which downregulate the concentration of the circulating sex
hormone-binding globulin, resulting in an increased fraction of
bioavailable estradiol, but decreased testosterone production [82].
Prospective studies suggest this increased bioavailability of sex
steroids, especially estrogen which is strongly associated with risk
of endometrial and postmenopausal breast cancer [52]. The prolifer-
ative effect of estrogen on epithelial tissue of both breast and
endometrium is believed to be the underlying mechanism.
3.2. Inﬂammation
It is well recognized that inﬂammation is involved in the
promotion and progression of cancer [83–85]. Obesity is associated
to systemic low-grade inﬂammation, which has been suggested to
have an important role in the pathogenesis of some disorders such as
insulin resistance, atherosclerosis and cancer [61,86]. In obesity, theexpandingWAT makes a substantial contribution to the development
of obesity-linked inﬂammation via dysregulated secretion (from both
by adipocytes and the non-adipocyte fraction) of pro-inﬂammatory
cytokines (Interleukin (IL)-6 and 1 and tumor necrosis factor alpha,
TNF-α), chemokines (monocyte chemotactic protein 1, MCP-1) and
adipokines (haptoglobin, PAI-1, leptin, visfatin, resistin and vascular
endothelial growth factor, VEGF) and the reduction of anti-inﬂam-
matory adipokines (e.g. adiponectin, IL-10, antagonist IL-1) [87,88].
The precise role of these inﬂammatory components in carcinogenesis
is not completely understood and therefore continues to be an
appealing avenue of research.
TNF-α plays an important role in adaptive responses of the
immune system and other organ systems. The anti-tumor effects of
TNF-α have been related to activation of Caspase 3 and induction of
apoptosis [89]. However, recent studies have suggested that TNF-α is
involved in carcinogenesis because of its ability to activate NF-κB [90].
In almost all cell types, when exposed to TNF-α, NF-κB is activated
and leads to the expression of a variety of inﬂammation-related genes.
Also TNF-α appears to contribute to the development of the tissue
architecture necessary for tumor growth and metastasis [91,92]. It
also induces other cytokines, angiogenic factors and matrix metallo-
proteinases (MMPs) and thus drives to the increased growth and
survival of tumor cells [93]. These tumor-promoting activities suggest
that inhibition of TNF-α is an effective strategy for cancer therapy.
Indeed, clinical trials with several TNF-α antagonists have shown
promising effects. For example, D2E7 (a fully humanized anti-TNF-α
monoclonal antibody), inﬂiximab (a chimeric immunoglobulin G1
monoclonal antibody against TNF-α), pegylated recombinant hu-
manized sTNF-R1, pegylated humanized anti-TNF-α fragment
(CDP870) and TNF-α synthesis inhibitors (p38 kinase inhibitors)
have been used to treat various tumors [94].
On the other hand, IL-6 is a pleiotropic inﬂammatory cytokine,
involved in the maturation of B cells, with described cancer-
stimulatory [95] and also cancer-inhibitory properties [96]. IL-6 is
an important regulator of immune cell growth and differentiation.
Recent studies have demonstrated that IL-6 regulates chronic
inﬂammation, which can create a cellular microenvironment beneﬁ-
cial to cancer growth [95]. High circulating IL-6 concentrations in
obesity correlated with overall cancer death and increased risk of
cancer precursor lesions [78]. The activation of the IL-6 complex
activates Janus kinases (JAK) and the signal transducer and activator
of transcription 3 (STAT3) pathways, which regulate cell proliferation
and apoptosis [97].
Obesity-induced inﬂammation involves other inﬂammatory com-
ponents that could contribute to the development of cancer. These
components include MMPs, which are associated with cancer-cell
invasion and metastasis [78], suggesting that the strongly induced
mRNA levels of several MMPs in obesity, as well as their role in
adipocyte differentiation, might represent a potential molecular link
between obesity and cancer.
3.3. Adipokines
3.3.1. Adiponectin
Adiponectin is a hormone mainly secreted by adipose tissue, and
to a small degree is also produced by cardiac myocytes, muscle cells
and endothelial cells [98]. The most important functions of adipo-
nectin identiﬁed so far are anti-atherogenic, anti-inﬂammatory and
insulin-sensitivity effects. In contrast to other adipokines, circulating
levels of adiponectin are negatively associated with obesity, BMI,
visceral fat accumulation and insulin resistance [99]. Several case–
control studies have observed that serum adiponectin levels were
signiﬁcantly decreased in breast cancer patients [100]. One study
described that adiponectin levels were signiﬁcantly reduced in
postmenopausal women with breast cancer, but not in premeno-
pausal women and, most importantly, this inverse association with
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another study observed reduced adiponectin levels in both premen-
opausal and postmenopausal women with breast cancer, and found
that patients with serum adiponectin levels in the lowest tertile
exhibited signiﬁcantly larger tumors [102]. Moreover, in vitro studies
have demonstrated that adiponectin treatment suppressed cell
proliferation and caused cell growth arrest and apoptosis in breast
cancer cells [103]. Moreover, Brakenhielm et al. [104] reported that
adiponectin-induced antiangiogenesis and antitumor activity
involves caspase-mediated endothelial cell apoptosis. The role of
adiponectin in cancer etiology is not yet fully understood. Although it
is possible that adiponectin provides indirect protection against
carcinogenesis, by affecting insulin sensitivity and the inﬂammatory
state, adiponectin may have direct anti-carcinogenic effects. The
pathway that involves adiponectin and the adiponectin receptors,
AdipoR1 and R2 mediates the activation of AMP-activated protein
kinase (AMPK). Activated AMPK plays an important role in the
regulation of growth arrest and apoptosis by stimulating p53 and p21
[105]. Independent of AMPK activation, adiponectin decreases the
production of reactive oxygen species (ROS), which may result in
decreased activation of mitogen-activated protein kinases (MAPK)
and thereby inhibition of cell proliferation [78,100].
Moreover, the important anti-inﬂammatory and immunomodula-
tory properties of adiponectin could also contribute to its anti-
carcinogenic effects. Thus, adiponectin has been shown to inhibit
endothelial NF-κB signaling and to markedly reduce TNF-α produc-
tion in cultured macrophages. Moreover, adiponectin also induces the
production of anti-inﬂammatory cytokines IL-10 and IL-1RA in human
leukocytes [106].
In conclusion, the decreased plasma levels of adiponectin in
obesity may be associated with the increased risk of cancer in obesity.
Thus, it has been proposed that upregulation of adiponectin levels
might be of therapeutic use in the prevention or treatment of some
cancers [100].
3.3.2. PAI-1
PAI-1 is a serine protease inhibitor produced by endothelial cells,
stromal cells and adipocytes mainly in visceral adipose tissue. PAI-1
affects adipocyte differentiation and insulin signaling. Furthermore,
increased PAI-1 levels have been associated with obesity, as the result
of increased PAI-1 production from obese adipocytes [107].
Moreover, PAI-1 inhibits urokinase plasminogen activator (uPA),
which acts as an inducer of ﬁbrinolysis and extracellular matrix
degradation, and is associatedwith tumor cell invasion andmetastasis
[108]. Paradoxically, PAI-1 is involved in tumor growth, invasion,
metastasis, and angiogenesis by interacting with vitronectin, integ-
rins, and other components of the uPA system and by affecting the
extracellular matrix [78].
PAI-1 is a poor prognostic indicator for a number of cancers
including breast cancer. However, there is no single mechanism to
explain why an elevation in PAI-1 protein results in decreased patient
survival [109]. In this context, there are a number of studies that
suggest alternative roles for PAI-1 outside of the traditional protease
inhibitor role. Speciﬁcally, several studies have indicated that PAI-1
promotes tumor growth through an inhibition of apoptosis [110],
regulation of angiogenesis, as well as increased cell adhesion, and
increased migration. In addition to the role of PAI-1 in breast cancer
migration and invasion, it has been implicated in an inﬂammatory
response. Taking together the current knowledge, it has been
proposed that inhibition of PAI-1 might be a potential target in
cancer therapy [109].
3.3.3. Visfatin/ NAMPT/PBEF
Visfatin was identiﬁed as an adipokine highly expressed in visceral
fat of human subjects and rodents, whose plasma circulating levels
were positively correlated with the size of visceral fat depots. Besides,this adipokine seemed not to be correlated with subcutaneous fat
depots and consequently, it was termed visfatin (from visceral fat)
[111]. This adipocytokinewas initially discovered as pre-B cell colony-
enhancer factor (PBEF), because it favored the development of
lymphocyte B colonies [112]. Later on, it was described as nicotin-
amide phosphoribosyltranferase (NAMPT), a key enzyme that
catalyses the ﬁrst step in NAD biosynthesis from nicotinamide,
which widens considerably its biological perspective [113].
The role of visfatin in obesity and linked metabolic disorders
remains controversial [98]. Thus, several studies showed increased
levels of visfatin in obesity, diabetes mellitus, and cardiovascular
disease [114,115]. However, other studies reported lower levels of
visfatin in these diseases [116–118]. The discrepancies in clinical
studies may be attributed to the multifactorial regulation of visfatin as
well as to the lack of concordance between commercially available
visfatin assays [119]. Thus, more research is needed to better deﬁne
the role of visfatin in metabolic diseases.
Moreover, several studies have shown an increased expression of
Nampt/PBEF/visfatin in different types of cancers [120]. Thus, a recent
study suggests that visfatin plays a role in prostate cancer progression,
with particular relevance and emphasis in an obese population [121].
Furthermore, Wang et al. [122] described that NAMPT is prominently
overexpressed in human prostate cancer cells and that elevation of
NAMPT expression occurs early for the prostate neoplasia. Moreover,
the inhibition of NAMPT signiﬁcantly suppresses cell growth in
culture and growth of xenografted prostate cancer cells in mice.
Furthermore, they demonstrated that NAMPT knockdown sensitizes
prostate cancer cells to chemotherapeutic treatment [122]. Nakajima
et al. [123] observed that visfatin levels were gradually increased with
stage progression in gastric cancer patients. Visfatin has also been
related with breast cancer. In fact, visfatin has been shown to
stimulate proliferation of MCF-7 human breast cancer cells [124].
Moreover, FK866/APO866 and CHS828/GMX1777 are two known
inhibitors of visfatin and have been evaluated as anticancer agents in
the clinic [120].
3.3.4. Leptin
Leptin, a 16 kDa adipokine produced byWAT, plays a critical role in
the regulation of body weight and energy balance by inhibiting food
intake and stimulating energy expenditure. Circulating leptin levels
are actively transported through the blood-brain barrier and activates
the hypothalamic anorexigenic neurons POMC/CART (pro-opiomela-
nocortin; cocaine and amphetamine regulated transcript) while
inhibiting orexigenic NPY/AgRP (neuropeptide Y; agouti related
peptide) neuropeptides leading to decreased appetite [125]. The key
role of the leptin system in regulating body fat in animals and humans
is demonstrated by the severe hyperphagia and obesity caused by
leptin deﬁciency. However, leptin concentrations positively correlate
with total body fat mass. Thus, leptin serum levels are high in obese
subjects, suggesting that resistance to leptin action develops with
chronic overfeeding and obesity. Leptin circulating levels rapidly
decline under caloric restriction and weight loss [126].
Leptin has also shown to be involved in the inﬂammatory
response, the regulation of insulin sensitivity as well as with
carcinogenesis [127]. Leptin plays an important role in both adaptive
and innate immunity. Accordingly, the leptin receptor is found to be
expressed on a variety of immune cells. The most evident effects of
leptin on the modulation of adaptive immune responses have been
shown in leptin-deﬁcient mice (ob/ob) and humans, which exhibited
impaired immunity in parallel to metabolic disturbances [128]. These
alterations are reversed by the administration of recombinant leptin
[106]. With regard to innate immunity, leptin is a direct potent
chemoattractant for monocytes and macrophages and also upregu-
lates the phagocytic function of these leukocytes [127].
Leptin has also been shown to be a growth factor in cancer cell
lines [129]. Indeed, leptin caused stimulation of normal and tumorous
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angiogenesis [130]. Moreover, elevated circulating leptin levels have
been identiﬁed in patients with different types of cancer [128].
Numerous studies have investigated the complex mechanisms
involved in the relationship between obesity, leptin and different
cancers. Thus, Fig. 2 summarizes the potential pathways directly
linking dysfunctional adipose tissue to obesity and cancer.
3.3.4.1. Leptin and breast cancer. It has been suggested that leptin
induced proliferation of breast cancer cell lines, by activating JAK2–
STAT3, PI3K–Akt–GSK3, ERK1/2, and AP-1 pathways, increasing the
expression of proteolytic enzymes that are essential in metastatic
process and stimulating angiogenesis, which is needed for tumor
growth [131,132]. Speciﬁcally, in estrogen receptor-positive human
breast cancer cell lines, leptin exerts its effects through activation of
MAPK pathway [133,134]. Leptin itself can also enhance aromatase
activity in MCF-7 cells and increase the production of estradiol or
activate the telomerase which also promotes cell proliferation [135].
High levels of VEGF and leptin are strongly linked. Thus, leptin
signaling upregulates VEGF in human and mouse mammary tumor
cells (MT), which has been linked to worse prognosis of breast cancer,
but the speciﬁc molecular mechanisms are largely unknown. A recent
study demonstrated that leptin signaling regulates VEGF mainly
through HIF-1alpha and NF-κB, and suggested that disruption of
leptin signaling could be used as a novel way to treat breast cancer
[136]. However, different studies exploring serum leptin levels in
women with breast cancer showed inconsistent data. Thus, while
some studies observed elevated plasma leptin levels and increased
leptin gene expression and leptin receptor expression in breast cancer
patients, other investigations do not support a relationship between
systemic leptin levels and risk of breast cancer [87,131]. Further
studies are needed in order to investigate the relationship between
leptin and breast cancer as well as the underlying mechanisms.
3.3.4.2. Leptin and endometrial cancer. A close association between
high leptin levels, as a consequence of obesity, and endometrial cancer
has been described [137,138]. A recent study has shown that leptin
may promote cell proliferation of endometrial cancer cells by the
functional activation of cyclooxygenase-2 (COX-2) through JAK2/
STAT3, MAPK/ERK, and PI3K/AKT-dependent pathways, suggesting
that COX-2 may be a critical factor of endometrial carcinogenesis in
obesity [139].
3.3.4.3. Leptin and colorectal cancer. There is accumulating evidence
that leptin signaling might be involved in the development of colon
cancer. Thus, data from a cohort study detected an almost 3-fold
increased risk of colon cancer among people with high leptin levels
[140]. Another case–control study in Japanese women also suggested
that leptin substantially increases the risk of colorectal cancer [141].
Several in vitro experiments have also demonstrated a signiﬁcant
mitogenic activity of leptin in colonic epithelial cells [142,143]. Leptin
can induce proliferation through the activation of the NF-κB and
ERK1/2-dependent pathways [142,143], as well as by upregulating
the c-fos expression in colon cancer cells [144].
Diverse nutritional trials demonstrated that diets rich in fats that
increase circulating leptin promote carcinogenesis by stimulating
colon cell proliferation [131,144]. Other studies carried out in animals
supported the hypothesis that leptin is a growth factor in colonic
epithelium and therefore that hyperleptinemia promotes epithelial
dysplasia, which in turn promotes colorectal tumorigenesis. However,
the relationship between leptin and colorectal cancer is not fully
understood. Indeed, other research studies in rodents suggested that
leptin treatment may have some protective effects against colon
carcinogenesis [145]. Furthermore, controversial data were found
regarding the association between serum leptin and colorectal cancer
risk [128].3.3.4.4. Leptin and prostate cancer. Several studies showed association
between moderately elevated or high leptin levels with prostate
cancer risk [146]. Leptin levels have also been signiﬁcantly correlated
with testosterone and speciﬁc prostatic antigen [147]. Leptin may
interact with markers related to abdominal obesity such as sex
hormones or IGF-1 increasing the risk of developing prostate cancer
[131]. Several in vitro and in vivo studies reported that leptin increased
cell proliferation, via JNK activation, and induced suppression of
apoptosis, favoring tumor cell progression, invasion and metastasis
[147], corroborating the role of this adipokine on prostate cancer.
3.3.4.5. Leptin and esophageal cancer. Several authors proposed a link
between leptin and esophageal adenocarcinoma. In vitro studies
reported that leptin stimulates cell proliferation on human esopha-
geal cancer cells (OE-33, OE-19, KYSE-410) through activation of ERK
and epidermal growth factor receptor system and through a reduction
of apoptosis [128]. However, no studies have examined the associa-
tion between serum leptin and esophageal cancer risk. In this sense,
two recent case–control studies examined serum leptin concentra-
tions in patients with Barrett's esophagus [148] describing a 3-fold
increased risk of Barret's among men in the highest quartile of serum
leptin. However, Francois et al. [149] did not ﬁnd any association
between plasma leptin with the risk of Barrett's.
In summary, all the previous studies support the important
contribution of some key adipokines in the control of growth and
proliferation of different types of tumors (see Table 1).
3.4. Insulin resistance, obesity and cancer
Dysfunctional adipose tissue in obese subjects makes a key
contribution to the development of obesity-linked hyperinsulinemia
and insulin resistance. Insulin upregulates hepatic production of
IGF-1 and both act as growth factors able to promote cancer cell
proliferation and decrease apoptosis [150]. These IGF-1 effects are
mediated through several downstream signaling networks, including
the phosphatidylinositol 3-kinase (PI3K)–AKT systemand the Ras/Raf/
MAPK systems, respectively [151]. Moreover, clinical studies have
shown that patients with high levels of IGF-1 have an increased risk of
several types of cancer, including colorectal, prostate, and postmen-
opausal breast cancer. Hyperinsulinemia is also an independent risk
factor for breast cancer in postmenopausal women and increases the
risk of colorectal and endometrial cancer; however, some controver-
sial results have been found (reviewed by van Kruijsdijk et al. [78]).
3.5. Oxidative stress, obesity and cancer
Oxidative stress is generatingmuch recent interest mainly because
of its accepted role as a major contributor to the etiology of several
pathologies with serious public health implications such as obesity
and cancer [152,153]. Oxidative stress can result from an imbalance
between reactive species production and body antioxidant defences.
ROS primarily originate in mitochondria during oxidative phosphor-
ylation. The study of Furukawa et al. [152] found that increased
oxidative stress in accumulated fat is an early instigator of metabolic
syndrome and that controlling the redox state in adipose tissue is a
potentially useful therapeutic target for obesity-associated metabolic
syndrome. In fact, this and other trials have observed that oxidative
stress caused dysregulated production of adipokines, cytokines and
chemokines including adiponectin, leptin, resistin, PAI-1, IL-6, and
monocyte chemotactic protein-1 in adipocytes [154,155].
The role of oxidative stress in cancer is controversial. In fact, both
pro- and anti-cancer effects have been attributed to ROS. Thus,
increased ROS production control tumor cell proliferation and
enhance metastatic potential of tumor cells [156]. However, several
studies have suggested that a pharmacological regulation in favor of
increasing intracellular ROS and/or depleting protective reducing
Fig. 2. Potential pathways directly linking obesity with cancer. AdipoR1/R2, adiponectin receptor 1/2; AMPK, 5′-AMPactivated protein kinase; IGF-1, insulin-like growth factor-1;
IGF-1R, insulin-like growth factor-1 receptor; IKK, IκB kinase; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; IR, insulin receptor; IRS-1, insulin receptor substrate-1; JAK, Janus
kinase; MAPK, mitogen-activated-protein-kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; ObR, leptin receptor; PAI-1, plasminogen activator inhibitor-1;
PI3K, phosphatidylinositol 3-kinase; ROS, Reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor-α; TNF-R1, tumor necrosis
factor-receptor 1; TRADD, TNFRSF1A-associated via death domain; TRAF2, TNF receptor-associated factor 2; TSC2, tuberous sclerosis complex 2; uPA, urokinase-type plasminogen
activator; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Modiﬁed with permission from van Kruijsdijk et al. [78].
670 P.L. Prieto-Hontoria et al. / Biochimica et Biophysica Acta 1807 (2011) 664–678metabolites may lead to oxidative stress and resultant induction of
apoptosis for the treatment of cancer [157].
Uncoupling protein-2 (UCP2) is expressed widely including in
white adipose tissue, skeletal muscle, pancreatic islets, and central
nervous system. Although the function of UCP2 is controversial, UCP2
may play a role in lipid metabolism as well as in energy expenditure
Moreover, it has been suggested that UCP2may function as a sensor ofmitochondrial oxidative stress, being activated by ROS and providing
protection against ROS production [158]. In fact, loss of UCP2 function
may result in increased generation of ROS and reduced antioxidant
capacity, whereas UCP2 overexpression conveys cytoprotection to
various tissues by limiting oxidative injury [159,160]. These ﬁndings
suggest a role for UCP2 in physiological states associated with
oxidative stress including cancer [161]. In fact, cancer cell survival
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oxidative stress. UCP2 expression has been found to be increased in
different types of cancer, including human colon cancers, supporting
the idea that UCP2 is part of a novel adaptive response by which
oxidative stress is modulated in cancer [160]. However, it has been
considered that the physiologically signiﬁcant roles of UCP2 in the
protection against reactive oxygen species remain still circumstantial
[162].
3.6. Mitochondrial biogenesis, obesity and cancer
Mitochondrial dysfunction can lead to the development of several
metabolic diseases such as obesity and cancer. In this sense, several
studies have demonstrated that adipose mitochondrial biogenesis
was overwhelmingly suppressed in both genetic and high-fat diet-
induced rodent models of diabetes/obesity [163,164]. Peroxisome
proliferator-activated receptor gamma coactivator (PGC-1α) and the
NAD-dependent deacetylase SIRT1 have been characterized as master
regulators of mitochondrial biogenesis [165]. Both, the expression of
PGC-1α and SIRT1 are reduced in adipose tissue of obese subjects
[166,167].
Therefore, developing therapeutics to improve mitochondrial
function and/or biogenesis is an attractive strategy for preventing
these disorders (reviewed by Pérez-Matute et al. [168]). In this sense,
it has been recently demonstrated that the insulin sensitizer actions of
pioglitazone could be due, at least in part, to its stimulatory effects on
mitochondrial biogenesis in human subcutaneous adipose tissue
[169]. Moreover, it has been observed that part of the mitochondrial
dysfunction can be triggered by adverse nutrition conditions [170],
and that bioactive food components may contribute to improve
adipose tissue failure and mitochondria [171].
4. Molecular nutrition, energy metabolism and cancer
Cancer is known to be caused by a variety of factors including sed-
entary lifestyle, infections, radiation exposure and hormonal factors.
Furthermore, breast, prostate, colorectal, esophageal and liver cancers
seem to be also associated with dietary patterns. In fact, dietary factorsTable 1
Effects of different adipokines on cancer cells.
Cancer type Adipokines Model of study E
Breast cancer Adiponectin Breast cancer MDA-MB-231 cells In
Visfatin MCF-7 breast cancer cells St
an
PAI-1 MDA-MD-435 cell and human breast cancer cell P
an
Leptin MCF-7 breast cancer cells P
P
MCF-7 breast cancer cells P
MCF-7 breast cancer cells E
Endometrial cancer Leptin Human endometrial cancer cells P
M
Colorectal cancer Leptin Human colon cancer HT-29 cells, colonic
epithelial cells
St
p
Human colon cancer HT-29 cells treated with
sodium butyrate
In
Human colon cancer HT-29 cells, colonic
epithelial cells
St
c-
Prostate cancer Leptin DU145 and PC-3 human prostate cancer cells In
E
Visfatin Human prostate cancer cells O
in
Human prostate tissue and Ln CaP or PC-3 cells In
o
PAI-1 Human prostate cancer PC-3 cells P
Esophageal cancer Leptin Esophageal cancer cells (OE-33, OE-19,
KYSE-410)
St
gaccount for approximately 30% of tumors in industrialized countries
[172]. However, and despite these studies, there are some inconsis-
tencies caused by the multi-factorial and complex nature of cancer as
well as the different genetic background of individuals. In addition, not
all macronutrients affect genes and oncogene expression in the same
way [171]. Variation in cancer incidence among andwithin populations
with similar dietary patterns suggests that an individual's responsemay
reﬂect interactions with genetic factors, which may have ramiﬁcations
in gene, protein andmetabolite expression patterns (reviewed byDavis
and Milner [173]).
Nutrigenomics considers the relationship between a speciﬁc
nutrient or a diet and gene expression, whereas nutrigenetics deter-
mines how genetic variability affects the response to dietary pattern,
functional food or supplement for a speciﬁc health outcome [174]. The
speciﬁc ﬁelds of genome-health nutrigenomics and genome health
nutrigenetics are proposed on the premise that a more useful ap-
proach to the prevention of diseases caused by genome damage is to
take into consideration that (a) inappropriate nutrient supply can
cause sizeable levels of genomemutation and alter expression of genes
required for genome maintenance and (b) common genetic polymor-
phisms may alter the activity of genes that affect the bioavailability of
micronutrients and/or the afﬁnity for micronutrient cofactors in key
enzymes involved in DNA metabolism or repair. Supplementation of
the diet with appropriate minerals and vitamins could, in some cases,
help to overcome inherited metabolic blocks in key DNAmaintenance
pathways [175,176].
In fact, during the last few years, research focused on the study of
the mechanisms underlying the beneﬁcial effects of bioactive food in
energy metabolism and cancer. It is important to remember that an
excess body weight is generally linked to enhanced cancer risk
[32,33,35]. Thus, a large number of bioactive food components
occurring in food may provide protection at several stages of the
cancer process. Representative bioactive components found in food
that are protective against cancer include essential nutrients (i.e.,
calcium, zinc, selenium, folate, Vitamins C, D and E) as well as non-
essential food components (i.e., carotenoids, ﬂavonoids, indoles, allyl
sulfur compounds, conjugated linoleic acid, n-3 fatty acids, and lipoic
acid) [177]. These bioactive food components may modifyffects and proposed mechanism of action Reference
duced growth arrest and apoptosis [103]
imulated cell proliferation by upregulating cyclin D1 and cdk2
d MMP-2, MMP-9, and VEGF
[124]
romoted tumor growth by inhibition of apoptosis, regulation of
giogenesis and by increasing cell adhesion and migration
Reviewed by [109]
roliferation of breast cancer cells by activation of JAK2–STAT3,
I3K–Akt–GSK3, ERK1/2, MAPK and AP-1
[131–133]
romoted cell proliferation by upregulating telomerase activity [135]
nhanced aromatase expression via AP-1 [134]
romoted cell proliferation by activation of COX-2, JAK2/STAT3,
APK/ERK, and PI3K/AKT
[139]
imulated proliferation of colon cancer cell lines by activating
42/44 MAPK
[142]
duced proliferation by activation of NF-κB and ERK1/2 [143]
imulated growth and proliferation and upregulation of
fos expression
[144]
creased cell proliferation through JNK, PI3K/Akt or
RK1/2 pathways, and suppression of apoptosis
Reviewed by [147]
verexpression of NAMPT increased prostate cancer cell by
creasing FOXO3 and oxidative stress resistance
[122]
creased PC-3 cell proliferation and the expression and activity
f MMP-2 and -9 by activating MAPK, ERK 1/2 and p38.
[121]
romoted tumor growth through inhibition of apoptosis [110]
imulates cell proliferation by activation of ERK and epidermal
rowth factor receptor system. Suppression of apoptosis.
[128]
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as hormonal balance, cell signaling, cell-cycle control, apoptosis, and
angiogenesis [178].
4.1. Dietary fatty acids, obesity and cancer
Dietary factors that potentially increase the risk of cancer include
low fruit, vegetable, or ﬁber intake, high red meat or saturated fat
consumption, and exposure to caffeine or alcohol [179]. Some case–
control and cohort studies have also found positive associations be-
tween dietary glycemic index (a physiological assessment of a
food's carbohydrate content through its effect on postprandial blood
glucose concentrations), and risk of various cancers, including those
of the colon, breast, and prostate [180]. Among the numerous dietary
compounds that have been related to cancer, dietary lipids have been
revealed as signiﬁcative ones. Epidemiological and especially exper-
imental studies have established a relationship between dietary fat
and breast, colon and rectum tumors and, to a lesser extent, prostate
[181,182]. A growing body of evidence suggests that not only the
total amount of fat ingested, but also the type of fat included in the
diet contribute to the development of obesity and insulin resistance
[98]. Moreover, an expanding number of retrospective case–control
investigations have also found an increase in cancer risk with in-
creasing fat intake, especially with animal and saturated fat intake
[183]. Thus, the association of high red meat or saturated fat con-
sumption with increased colorectal cancer risk is supported by the
preponderance of observational data [184]. In contrast to diets high
in saturated fat, diets high in ﬁsh oil appear to prevent or attenuate
the development of obesity and insulin resistance [185–187] and
cancer [181].
4.1.1. n-3 Polyunsaturated fatty acids (n-3 PUFAs)
The n-3 PUFAs present in ﬁsh oil, are known to have numerous
beneﬁcial effects on health. These include improvement of endothe-
lial function, anti-arrhythmic effects, reductions in platelet aggregation
and serum triglyceride concentrations, and amelioration of pathological
conditions such as inﬂammatory diseases, hypertension and cancer.
Diets containing high levels of n-3 PUFAs have been shown to reduce
WAT and adipocyte size and to prevent non-insulin-dependent dia-
betes in rats. Indeed, eicosapentaenoic acid (EPA) [20:5 (n-3)], one of
the prominent n-3 PUFAs contained in ﬁsh oil, has been reported to be
useful in preventing the onset of insulin resistance and diabetes in
animal models of obesity and diabetes [188].
Regarding the mechanisms underlying the beneﬁcial effects of
marine n-3 PUFA consumption, it was demonstrated that n-3 PUFA are
important regulators of key metabolic transcription factors including
the peroxisome proliferator-activated receptors (PPARs) and sterol
regulatory element binding protein (SREBP) [98]. n-3 PUFAs have
anti-inﬂammatory effects in a range of chronic inﬂammatory condi-
tions, because their ability to decrease the production of classic
inﬂammatorymediators such as arachidonic acid-derived eicosanoids
and inﬂammatory cytokines. Moreover, it was recently described that
n-3 PUFAs serve as substrates for the conversion to a novel series of
lipid mediators designated resolvins and protectins, withmore potent
anti-inﬂammatory properties than their n-3 precursors [189].
AMPK activation could be also involved in n-3 PUFA-induced
improvements on energy metabolism and insulin sensitivity. A recent
study of our group has demonstrated that EPA strongly stimulates
AMPK phosphorylation in 3T3-L1 adipocytes [190]. Moreover, two
recent trials have described the ability of n-3 PUFAs to in vivo activate
AMPK [191,192]. n-3 PUFAs have also been shown to upregulate
mitochondrial biogenesis and induce beta-oxidation in white fat in
mice, associated with a three-fold stimulation of the expression of
genes encoding regulatory factors for mitochondrial biogenesis and
oxidative metabolism such as PGC-1α and nuclear respiratory factor-
1 (Nrf-1) [193].Furthermore, the beneﬁcial properties of n-3 PUFAs may also
partially result from the modulation of WAT metabolism and the
secretion of bioactive adipokines that directly regulate energy homeo-
stasis, insulin sensitivity and carcinogenesis. Thus, different studies of
our group and others have shown that n-3 PUFAs are important
regulators both in vitro and in vivo of the secretion and gene expression
of leptin [188,194], adiponectin [194–196], visfatin [118,190] and apelin
[118,197], among other adipokines.
The proposed mechanisms for the anticancer actions of n-3 PUFAs
include suppression of neoplastic transformation, inhibition of cell
proliferation, enhancement of apoptosis, and antiangiogenic. A recent
study suggests that n-3 PUFAs inhibit hepatocellular carcinoma cell
growth through blocking beta-catenin and cyclooxygenase-2 [153].
Another investigation suggests that DHA induce apoptosis in human
MCF-7 breast cancer cells both in vitro and in vivo. The induction of
apoptosis in these cells is selectively mediated via caspase 8 activation
[198]. Recently, it has been suggested that resolvins biosynthesized
from n-3 PUFAs may play a role as anti-inﬂammatory and proresol-
ving mediators in colon cancer [199].
4.1.2. Conjugated linoleic acid (CLA)
CLA was initially discovered in 1987 by Ha et al. [200] and it was
ﬁrst identiﬁed as an anticarcinogen molecule. Several studies have
indicated that CLA exert anti-obesity effects in rodents, although its
effects in humans are controversial. The potential mechanisms
responsible for the antiobesity properties of 10,12-CLA isomer in
rodent models include decreased energy intake by suppressing
appetite, increased energy expenditure, decreased lipogenesis and
adipogenesis, increased lipolysis and apoptosis [201,202]. Several
studies have also shown that CLA regulates both leptin and
adiponectin in vivo [203] and in vitro [194]. Furthermore, it has been
suggested that this inhibition of leptin and adiponectin induced by
CLA may contribute to the insulin resistance observed in some CLA-
treated animals and humans [204].
On the other hand, a number of assays have demonstrated that CLA
exerts chemopreventive and therapeutic activities in a number of
rodent and human tumor models. Thus, the 10t, 12c isomer of CLA
inhibits tumorigenesis and tumor growth in human breast (MCF-7),
colon (HT-29) and prostate (LNCaP) cancer cell lines. This inhibitory
effect of CLA on tumor growth is mediated in part by its pro-apoptotic
activity [205,206].
4.2. Antioxidants, obesity and cancer
The attenuation or complete suppression of oxidative stress as a
way to improve several diseases has ﬂourished as one of the main
challenges of research in the last years. A number of trials have
examined the effects of supplementation with different antioxidants
on oxidative stress associated to obesity and/or cancer [205–213].
However, and although several positive effects have been found [207–
209] there are some controversial results, specially in the ﬁeld of
antioxidant supplementation and cancer. Thus, a trial found a
statistically signiﬁcant reduction in total and speciﬁc cancer incidence
and mortality after supplementation with antioxidants [210]. How-
ever, other studies observed a lack of effect of supplementation with
antioxidants on cancer [211,212]. Furthermore, the Alpha-Tocopherol
Beta-Carotene Cancer Prevention Study (ATBC) and the β-Carotene
and Retinol Efﬁcacy Trial, especially on lung cancers did not observe
reduction in the incidence of lung cancer among male smokers after
ﬁve to eight years of dietary supplementation with alpha-tocopherol
or beta carotene. In fact, these trials raise the possibility that these
supplements may actually have harmful as well as beneﬁcial effects
[213,214]. Vitamin C also seems to have a controversial role in cancer
[215]. Possible reasons for these discrepancies in relation to the
efﬁcacy of antioxidant to counteract oxidative stress and improve
health relate to (1) the type of antioxidant used (some of the
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regimen or duration of therapy were inefﬁcient), (2) patient cohort
included in trials, (3) the trial design itself and (4) inappropriate or
insensitive methodologies to evaluate oxidative state (reviewed by
Pérez-Matute et al., 2009 [168]).
4.3. Resveratrol, obesity and cancer
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is awell-known poly-
phenolic compound of red wine with numerous beneﬁcial activities,
including cardioprotective actions [216], anti-cancer effects [217] and
anti-inﬂammatory and antioxidant properties [218]. Recently, this
broad spectrum of effects is enlarged by new data demonstrating a
great potency of this compound in relation to obesity and diabetes. It is
well established that resveratrol exerts beneﬁcial effects in rodents
fed with a high fat diet, substantially reducing visceral fat and body
weight gain [219,220]. The mechanisms underlying these resveratrol
effects include: induction of genes for oxidative phosphorylation and
mitochondrial biogenesis (reviewed by Szkudelska and Szkudelski
[221]), inhibition of preadipocyte proliferation and adipogenic differ-
entiation, stimulation of basal and insulin-stimulated glucose uptake,
and inhibition of de novo lipogenesis [222]. Resveratrol may also
inﬂuence the secretion and plasma concentrations of some adipokines
such as adiponectin and TNF-α and inhibits leptin secretion from rat
adipocytes [223,224]. However, data regarding the effects of resveratrol
on adipokines are still insufﬁcient to be conclusive.
Several studies have suggested that activation of SIRT1 and AMPK
plays a key role in the metabolic effects of resveratrol [225,226]. A
recent research has also shown that resveratrol modulates tumor
cell proliferation and protein translation via SIRT1-dependent AMPK
activation [227]. In this context, resveratrol has been proposed as a
potential dietary compound against various cancers including breast
and colon tumors. Resveratrol may affect all three discrete stages of
carcinogenesis (initiation, promotion, andprogression) bymodulating
signal transduction pathways that control cell division and growth,
apoptosis, inﬂammation, angiogenesis, andmetastasis [228]. Recently,
it has been shown that resveratrol suppresses IGF-1 induced cell
proliferation and elevates apoptosis in human colon cancer cells, via
suppression of IGF-1R/Wnt and activation of p53 signaling pathways
[217].
4.4. Lipoic acid, obesity and cancer
α-Lipoic acid (LA) or 1,2-dithiolane-3-pentanoic acid is a prom-
ising dietary bioactive molecule because of its recognized therapeutic
potential on several diseases such as diabetes, vascular disease,
hypertension and inﬂammation [229]. Both LA and its reduced form
dihydrolipoic acid (DHLA) exert powerful antioxidant properties
although DHLA seems to be a more effective [230]. Their antioxidants
functions involve: quenching ROS (reactive oxygen species), regen-
eration of endogenous and exogenous antioxidants involving vitamin
C, vitamin E and glutathione, chelation of redox metal including Cu
(II) and Fe (II) and repair of oxidized proteins. LA can be found in
different foods such as spinach and cabbage, liver and meat, whole
wheat and yeast of beer, but it is also endogenously produced by the
liver through the lipoic acid synthase (LASY) machinery. Deﬁciency of
LASY results in an overall disturbance in the antioxidant defence
network, leading to increased inﬂammation, insulin resistance and
mitochondrial dysfunction [231].
LA is an important cofactor for mitochondrial bioenergetic
enzymes, and therefore, plays a critical role in mitochondrial energy
metabolism [232,233]. In addition, there are increasing scientiﬁc and
medical interests in the potential therapeutic uses of LA. In this sense,
several studies have described the putative beneﬁts of LAonobesity and
associated complications. Thus, LA reduces body weight and adiposity
in rodents [234,235] and humans [236]. Several mechanisms maycontribute to the anti-obesity effects of LA including the suppression of
hypothalamic AMPKactivity [237], which in turn leads to a reduction on
food intake, and the stimulation of energy expenditure by increasing
Ucp-1 mRNA levels in brown adipose tissue [234] and by enhancing
adenosine monophosphate-activated protein kinase (AMPK)-peroxi-
some proliferator-activated receptor-gamma coactivator-1 alpha (PGC-
1α) signaling in the skeletal muscle [238]. Furthermore, the inhibitory
action of LAon intestinal sugar transport could also contribute to a lower
feed efﬁciency observed in LA-treated animals [235].
In addition, LA has also beneﬁcial actions in both glucose and lipid
metabolism, and it has been proposed as a potential therapy for
insulin resistance and type 2 diabetes [239–241]. LA positively
interacts with the insulin pathway and glucose handling in muscle
and adipocytes, by modulating the IR/PI3K/Akt pathway and GLUT4
translocation [229]. LA also promotes mitochondrial biogenesis in
adipocytes and muscle through a stimulation of PGC-1α, contributing
to improve the defective mitochondrial function associated to dia-
betes/obesity [242,243].
Several trials have also suggested the potential use of LA in cancer
therapy [244] due to its ability to induce apoptosis in cancer cells
[245,246]. However, the molecular mechanisms underlying the
apoptotic effect of LA are not well understood. Shi et al. [246]
suggested that the inhibition of ROS generation mediated LA-induced
apoptosis in hepatoma cells. Moreover, LA, through scavenging ROS,
inhibits PI3K signaling and induces mitochondrial pathway mediated
apoptosis [246]. However, Moungjaroen et al. [247] demonstrated
that LA induced-ROS generation mediates caspase activation and
apoptosis in human lung epithelial cancer cells through Bcl-2
downregulation.
A recent study have suggested that LA exerts an inhibitory effect
on cell proliferation via EGFRs and Akt signal transduction and
induces cancer cell apoptosis in MDA-MB-231 human breast cancer
cells [248]. Further studies are needed to better characterize the
mechanisms involved in the anti-carcinogenic action of LA.
5. Perspectives
There is emerging evidence of strong associations between obe-
sity and the incidence of cancer. In obesity, the expanding adipose
tissue could make a clinically relevant contribution to the onset and
development of cancer via dysregulated secretion of pro-inﬂammatory
cytokines, chemokines and adipokines such as TNF-α, IL-6, leptin,
adiponectin and PAI-1. More investigation in order to better under-
stand the molecular mechanisms that link dysregulated adipose
tissue function and cancer is worth pursuing, as it may provide new
therapeutic targets to prevent or treatment in cancer. Nevertheless,
tackling obesity is a priority for reducing the incidence in addition to
mortality of certain cancers. The identiﬁcation of bioactive dietary
factors or substances that affects some of the components of energy
balance to prevent/reduce weight gain is a promising avenue of
research. However, the mechanisms by which dietary components
modulate obesity and cancer are not fully understood, partly because
of the lack of appropriate research tools to identify the complex
mechanisms involved. With the emergence of Nutrigenomics, it is
now possible to exploit genome-wide changes in gene expression
proﬁles related to molecular nutrition in obesity and cancer. Evolution
of ‘-omics’ epigenomics, transcriptomics, proteomics, andmetabolomics
will allow a better understanding of how dietary factors may affect
both energy metabolism and carcinogenesis, leading to healthier foods
and, in turn, healthier people and lifestyles.
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